Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-275-1933
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.07 million
Profitability
Miscellaneous
Employees8
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions
What is Innovate Biopharmaceuticals' stock symbol?
Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."
How were Innovate Biopharmaceuticals' earnings last quarter?
Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its earnings results on Thursday, August, 8th. The company reported ($0.13) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.13). View Innovate Biopharmaceuticals' Earnings History.
When is Innovate Biopharmaceuticals' next earnings date?
What price target have analysts set for INNT?
1 equities research analysts have issued 1-year target prices for Innovate Biopharmaceuticals' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Innovate Biopharmaceuticals' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 843.4% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.
What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.
Has Innovate Biopharmaceuticals been receiving favorable news coverage?
News stories about INNT stock have trended negative on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Innovate Biopharmaceuticals.
Are investors shorting Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,070,000 shares, a drop of 15.1% from the August 30th total of 1,260,000 shares. Based on an average daily volume of 163,700 shares, the short-interest ratio is presently 6.5 days. Approximately 4.7% of the company's stock are sold short. View Innovate Biopharmaceuticals' Current Options Chain.
Who are some of Innovate Biopharmaceuticals' key competitors?
Some companies that are related to Innovate Biopharmaceuticals include Satsuma Pharmaceuticals (STSA), Sol Gel Technologies (SLGL), Hookipa Pharma (HOOK), Cerecor (CERC), Five Prime Therapeutics (FPRX), Axovant Sciences (AXON), Arcturus Therapeutics (ARCT), AVEO Pharmaceuticals (AVEO), Calithera Biosciences (CALA), REDHILL BIOPHAR/S (RDHL), Northwest Biotherapeutics (NWBO), Avadel Pharmaceuticals (AVDL), Harrow Health (HROW), American Brivision (Holding) (ABVC) and Axovant Gene Therapies (AXGT).
What other stocks do shareholders of Innovate Biopharmaceuticals own?
Who are Innovate Biopharmaceuticals' key executives?
Innovate Biopharmaceuticals' management team includes the folowing people:
- Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
- Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
- Dr. Christopher P. Prior, Consultant (Age 66)
- Jerry Gardner M.D., Head of Clinical Strategy
- Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)
How do I buy shares of Innovate Biopharmaceuticals?
Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Innovate Biopharmaceuticals' stock price today?
One share of INNT stock can currently be purchased for approximately $1.06.
How big of a company is Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals has a market capitalization of $38.04 million and generates $4.07 million in revenue each year. The company earns $-24,160,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe.View Additional Information About Innovate Biopharmaceuticals.
What is Innovate Biopharmaceuticals' official website?
How can I contact Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]
MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
